Attention!

What is the drug ICATIBANT-CHEMRAR

ICATIBANT-CHEMRAR is a selective competitive antagonist of bradykinin B2 receptors, a synthetic decapeptide, similar in structure to bradykinin, but contains 5 non-proteinogenic amino acids.

The formation of bradykinin from high-molecular kininogen occurs with the participation of kallikrein. About 40% of plasma kallikrein is inactivated by a C1-esterase inhibitor. Deficiency or dysfunction of the C1-esterase inhibitor leads to an increase in the content of kallikrein in plasma. This contributes to an increase in the content of bradykinin, which is the main biologically active substance that determines the development of clinical symptoms of angioedema, directly causing increased vascular permeability, vasodilation, and contractions of smooth muscles of visceral organs. Therefore, after exposure to the etiological factor against the background of a C1-esterase inhibitor deficiency, it leads to excessive bradykinin production, followed by a pronounced increase in vascular permeability.

Icatibant acts as a bradykinin inhibitor by blocking the binding of endogenous bradykinin to bradykinin B2 receptors, which prevents the development of the pharmacological action of bradykinin.

Dosage form

The solution for subcutaneous injection is transparent, colorless or with a slightly yellowish tinge. 3 ml syringes, pre–filled with an injection needle (25G, 16 mm) - blister packs - cardboard packs.

Indications for use

Symptomatic treatment of acute attacks of hereditary angioedema in adults with C1-esterase inhibitor deficiency.

Efficacy and safety studies

In accordance with the current legislation, the drug has proven its effectiveness, safety and quality during state registration.